News & Updates
AMP PD Release 4.1 Release Notes – September 2024
AMP PD’s latest update to the release v4 dataset adds new whole-blood bulk RNA samples from the HBS cohort, bringing the total from 8461 to 10609! These longitudinal samples were selected for multiple timepoints per participant to enrich transcriptomic analyses that measure progression. All participants for these new HBS samples have matching WGS and clinical data, adding breadth and depth to the unified AMP PD dataset.
Data Summary
Data Composition
AMP PD's release 4.1 adds 2148 longitudinal RNASeq samples to the release v4 data, bringing the total fully-integrated (Clinical, WGS, and Transcriptomics) participants up 25% from 3036 to 3785. This release update also includes 251 plasma based proteomics samples in two targeted autoantibodies datasets contributed by AbbVie.
Overall data composition now includes 10,908 participants from the Unified Cohort (including BioFIND, HBS, LBD, LCC, PDBP, PPMI, STEADY PD, and Sure PD) and the Postmortem Brain Cohort. AMP PD includes clinical data for all participants, as well as whole genome sequencing data for 10,432 participants, transcriptomics data for 4,023 participants, and proteomics data for 695 participants including targeted (n=413) and untargeted (n=621) analyses. AMP PD sample tissue sources include CSF, plasma, whole blood, as well as extracellular vesicles and single nucleus brain tissue from five brain regions.
V4.1 Release Update Summary
Additions
New samples: HBS cohort whole blood bulk RNASeq samples
New data type: AbbVie contributed autoantibodies proteomics datasets from plasma
New Terra workspace:
- AMP PD Autoantibodies workspace and a “Start Here Autoantibodies” notebook . Registered AMP PD researchers can access it (here)
Changes
None